Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Magnevist

(Gadolinium)

Phase 2Small molecule

OOHSU Knight Cancer Institute

Gadolinium is a contrast agent used during MRI scans to help doctors see certain body structures and tissues more clearly by making them appear brighter in the images.[1] Magnevist is currently being investigated across 11 indications[3], with its most advanced program in Phase 2.[1]

Magnevist is one of 276 small molecule programs targeting Radiculopathy. It is currently in Phase 2.

11

Indications

29

Total Trials

7

Active Trials

275

Competitors

Pipeline

Status by Indication[3][1]

Indication

RadiculopathyActive, not recruiting

Alzheimer DiseaseActive, not recruiting

SepsisActive, not recruiting

Neurofibromatosis Type 1Active, not recruiting

Brain NeoplasmActive, not recruiting

Prostate CancerUnknown

Acute Myeloid LeukemiaRecruiting

Multiple SclerosisActive, not recruiting

AcromegalyActive, not recruiting

Brain MetastasesRecruiting

RadiculopathyPreclinical

Active, not recruiting

Alzheimer DiseasePreclinical

Active, not recruiting

SepsisPreclinical

Active, not recruiting

Neurofibromatosis Type 1Preclinical

Active, not recruiting

Brain NeoplasmPreclinical

Active, not recruiting

Prostate CancerPreclinical

Unknown

Acute Myeloid LeukemiaPhase 1

Recruiting

Multiple SclerosisPreclinical

Active, not recruiting

AcromegalyPreclinical

Active, not recruiting

Brain MetastasesPhase 2

Recruiting

Competition

Competitive Landscape

314 competitors in Prostate Cancer

#DrugCompanyPhaseTrials

Lupron

EEastern Cooperative Oncology Group

Glucophage

Cortef

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

LHRH Agonist

Lutetium Lu-177 PNT2002

JJonsson Comprehensive Cancer Center

Magnevist

OOHSU Knight Cancer Institute

Gallium Ga 68 Gozetotide

SHR3680

JJiangsu HengRui Medicine Co., Ltd.

Rhpsma-7.3 (18f)

BBlue Earth Diagnostics

Trexall

Jazz Pharmaceuticals

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Brain Tumors

NCT03067467

Q2 2027

Phase 1Recruiting

Imaging

NCT02648009

Q3 2027

Phase 1Recruiting

Acute Myeloid Leukemia

NCT02390635

Q2 2028

Phase 2Recruiting

Brain Metastases

NCT05692635

Clinical

Trials by Indication[1]

Brain Tumors4 trials

Ferumoxytol in Improving MR Imaging in Patients With High-Grade Brain Tumors or Cerebral Metastases

Completed·OOHSU Knight Cancer Institute·N/A·NCT00103038·155 enrolled

Metabolic Characteristics of Brain Tumors Using Hyperpolarized Carbon-13 Magnetic Resonance Spectroscopic Imaging (MRSI)

Recruiting·UUniversity of Texas Southwestern Medical Center··NCT03067467·25 enrolled

Ferumoxytol- and Gadolinium-Labeled MRI in Measuring Tumors Before or After Treatment in Patients With Primary or Metastatic Brain Tumors

Terminated·OOHSU Knight Cancer Institute·Phase 2·NCT00659126·40 enrolled

Show 1 more trial

DSC-MRI With Ferumoxytol and DCE-MRI With Gadolinium in Imaging Vascular Properties in Younger Patients With Brain Tumors

Completed·OOHSU Knight Cancer Institute·Phase 1·NCT00978562·14 enrolled

Glioblastoma2 trials

Correlation Between the Genetic and Neuroimaging Signatures in Newly Diagnosed Glioblastoma Patients Before Surgery

Withdrawn·OOhio State University Comprehensive Cancer Center·N/A·NCT02590497

Study of Tumor Treating Fields With Hypofractionated Chemoradiotherapy in Newly Diagnosed Glioblastoma

Completed·SStanford University·Phase 1·NCT04474353·12 enrolled

Glioblastoma Multiforme2 trials

MRI Study With Ferumoxytol in Assessing Early Response in Patients With Glioblastoma Multiforme Receiving Temozolomide and Radiation Therapy

Completed·OOHSU Knight Cancer Institute·N/A·NCT00660543·14 enrolled

Feasibility of [¹⁸F]-Fluoromisonidazole (FMISO) in Assessment of Malignant Brain Tumors

Recruiting·OOHSU Knight Cancer Institute·Phase 2·NCT03649880·77 enrolled

Psoriasis1 trial

ASIS for Enbrel in Plaque Psoriasis

Unknown status·AASIS Corporation·Phase 1/2·NCT02112097·60 enrolled

Heart Disease1 trial

Comprehensive Evaluation of Ischemic Heart Disease Using MRI

Completed·NNorthwestern University·Phase 2/3·NCT01234870·40 enrolled

19 more indications

Pilot Study1 trial

Ventilation and Pulmonary Endothelium Toxicities of E-cigarettes: A Randomized Crossover Pilot Study

Completed·—·Phase 1·NCT02783768·12 enrolled

AIN1 trial

Evaluation of Inner Ear and Brain Structures With Contrast-enhanced MRI in Patients With Meniere's Disease

Terminated·UUniversity Hospital, Grenoble·Phase 4·NCT02530931·23 enrolled

Injury1 trial

Impact of Pediatric Acute Renal Injury in Severe Sepsis in Young Adults

Withdrawn·UUniversity of Florida··NCT02599844

Cervical Dystonia1 trial

ASIS for Botox in Cervical Dystonia

Unknown status·Lli nguyen·Phase 1/2·NCT02074293·60 enrolled

Prostate Cancer1 trial

18F-DCFPyL PET/MRI in Regional Nodal&Distant Metastases Detection in Intermediate &HR Prostate Cancer

Approved for marketing·SStanford University··NCT04809584

Chronic1 trial

Chronic Convection Enhanced Delivery of Topotecan

Completed·—·Phase 1·NCT03154996·5 enrolled

Acromegaly1 trial

Cardiac (CMRI) Assessment of Acromegaly

Completed·AAssistance Publique - Hôpitaux de Paris·N/A·NCT02948322·28 enrolled

Imaging1 trial

Metabolic Imaging of the Heart Using Hyperpolarized (13C) Pyruvate Injection

Recruiting·SSunnybrook Health Sciences Centre·Phase 1·NCT02648009·112 enrolled

Migraine1 trial

ASIS for Botox in Chronic Migraine

Unknown status·AASIS Corporation·Phase 1/2·NCT02074163·60 enrolled

Allograft1 trial

Stress Cardiac MRI for Evaluation of Nonspecific Allograft Dysfunction

Completed·PPaul Kim·Phase 4·NCT02597543·14 enrolled

Sepsis1 trial

Severe Sepsis in Children - IMPRESS-C

Withdrawn·UUniversity of Florida··NCT02598674

Spasticity1 trial

ASIS for Botox in Upper Limb Spasticity

Unknown status·Lli nguyen·Phase 1/2·NCT02074150·60 enrolled

ESS1 trial

A Feasibility Study to Assess the Use of Gadolinium in Computed Tomography

Withdrawn·MMassachusetts General Hospital·Phase 4·NCT02163005

Epilepsy1 trial

Investigation of Blood-Brain-Barrier Breakdown Using Manganese Magnetic Resonance Imaging in Drug-Resistant Epilepsy

Recruiting·NNational Institute of Neurological Disorders and Stroke (NINDS)·Phase 1·NCT02531880·40 enrolled

Acute Myeloid Leukemia1 trial

PET/MR, PET/CT and Whole Body MR in Newly Diagnosed Acute Myeloid Leukemia (AML)

Recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT02390635·77 enrolled

Central Nervous System Neoplasm1 trial

The Feasibility of Steady State CBV Mapping Using Ferumoxytol Immediately After Gadolinium Enhanced MRI of the CNS

Recruiting·OOHSU Knight Cancer Institute·Phase 2·NCT03270059·150 enrolled

Brain Metastases1 trial

Reducing the Incidence of Symptomatic Brain Metastases With MRI Surveillance in Non-Squamous Locally Advanced Non-Small Cell Lung Cancer

Recruiting·WWake Forest University Health Sciences·Phase 2·NCT05692635·60 enrolled

LMS - Leiomyosarcoma1 trial

Phase 2 Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) With Gemcitabine Followed by Systemic Adjuvant Chemotherapy With Dacarbazine for Locally Recurrent Uterine Leiomyosarcoma (LMS)

Completed·SStanford University·Phase 2·NCT04727242·17 enrolled

Unspecified1 trial

Use of Gadolinium in CT Pulmonary Angiography

Withdrawn·MMassachusetts General Hospital·Phase 4·NCT02234375

Sources

References

[1]
ClinicalTrials.gov — 29 trial records for Gadolinium. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Gadolinium compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Gadolinium. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — OHSU Knight Cancer Institute company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: OOHSU Knight Cancer Institute

Related News